[Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer].
Enzyme immunoassay CYFRA 21-1, a novel lung tumor marker presented in serum (upper limit of normal values: 3.5 ng/ml) was measured in 84 patients with lung cancer and 141 patients with benign respiratory diseases. The positive rate for CYFRA 21-1 in primary lung cancer was 70.3% and the false positive rate in respiratory diseases was 24.1%. In respect to the histological types of lung cancer, CYFRA 21-1 was elevated in 85.0% of squamous cell carcinoma and in 64.8% of other cell types of primary lung cancer. Elevated CYFRA 21-1 levels were found in 40% of Stage I-II, in 80.0% of Stage IIIA-B, and in 73.5% of Stage IV. The overall diagnostic efficiency was 53.4% for CYFRA 21-1 and 44.5% for CEA, respectively. Receiver operating characteristic (ROC) curve analysis suggested that CYFRA 21-1 test has an advantage over CEA. From the results of this study, CYFRA 21-1 was more efficient than CEA as primary diagnostic marker in lung cancer.
Satoh
H
H
Dept. of Internal Medicine, University of Tsukuba.
Yagyu
H
H
Sumi
M
M
Ishikawa
H
H
Hamada
M
M
Suyama
T
T
Naitoh
T
T
Inoue
M
M
Saitoh
T
T
Uchida
Y
Y
D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000175:diagnosis; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000175:diagnosis; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007633:Keratins / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood* / Q000175:diagnosis; D008297:Male; D011379:Prognosis
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D007633:Keratins